|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||0|
|Avg. Monthly Volume||0|
|Avg. Quarterly Volume||0|
Amryt Pharma plc (NASDAQ: AMYT) stock closed at 14.7 per share at the end of the most recent trading day (a 0.07% change compared to the prior day closing price) with a volume of 2.38M shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 88 people. Amryt Pharma plc CEO is Joseph Amrit Wiley.
The one-year performance of Amryt Pharma plc stock is %, while year-to-date (YTD) performance is 101.37%. AMYT stock has a five-year performance of %. Its 52-week range is between and , which gives AMYT stock a 52-week price range ratio of %
Amryt Pharma plc currently has a PE ratio of 18.90, a price-to-book (PB) ratio of 1.38, a price-to-sale (PS) ratio of 3.84, a price to cashflow ratio of 4.30, a PEG ratio of 2.32, a ROA of -0.11%, a ROC of 3.01% and a ROE of -0.27%. The company’s profit margin is -22.42%, its EBITDA margin is 36.30%, and its revenue ttm is $241.60 Million , which makes it $3.78 revenue per share.
Of the last four earnings reports from Amryt Pharma plc, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Amryt Pharma plc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Amryt Pharma plc is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Amryt Pharma plc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amryt Pharma plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amryt Pharma plc has a Buy technical analysis rating based on Technical Indicators (ADX : 17.39, ATR14 : 0.06, CCI20 : 264.51, Chaikin Money Flow : 0.07, MACD : 0.07, Money Flow Index : 71.36, ROC : 1.03, RSI : 69.19, STOCH (14,3) : 71.43, STOCH RSI : 1.00, UO : 59.41, Williams %R : -28.57), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amryt Pharma plc in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).
CEO: Joseph Amrit Wiley
Telephone: +44 2030267257
Address: 196 High Road, London N22 8HH, , GB
Number of employees: 88
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.